



Precision Drug Design: Unlocking a new era in therapeutics discovery

Wednesday, April 6 or 13, 2021

3:00pm – 3:08pm

Welcome message

Dr. David Granville

Professor and Associate Dean, Research, Faculty of Medicine, UBC
Executive Director, VCHRI

3:08pm – 3:11pm

Moderator

Nancy Harrison

Venture Partner, Amplitude Ventures

3:11pm – 3:13pm

Speaker introduction

3:13pm – 3:23pm

Design, synthesis and development of the next generation of radiopharmaceuticals as precision oncology therapeutics

Dr. Lana Janes

CEO, Abdera Therapeutics

3:23pm – 3:25pm

Speaker introduction

3:25pm – 3:35pm

Back to the Future: Leveraging old data for new targets

Handol Kim

Co-Founder & CEO, Variational AI

3:35pm – 3:37pm

Speaker introduction

3:37pm – 3:47pm

XEN496: A phase 3 precision medicine for KCNQ2 developmental and epileptic encephalopathy

Dr. Robin Sherrington

Executive Vice President, Strategy and Innovation, Xenon Pharmaceuticals Inc.

3:47pm – 3:49pm

Speaker introduction

3:49pm – 3:59pm

Automated drug discovery through the use of artificial intelligence and big data

Dr. Artem Cherkasov

Head, Precision Cancer Drug Design, Vancouver Prostate Centre
Professor, Urologic Sciences, UBC

4:00pm – 4:25pm

Question & Answer

Speaker panel facilitated by moderator

4:25pm – 4:30pm

Closing remarks

Dr. David Granville